NCLT allows Shivinder to withdraw petition against his brother Malvinder. Final decision to be taken by family members in their presence.
Sources said she had stopped eating for the past few days and had constantly been making calls and sending emails to the two brothers.
Once the patients are identified, the government will decide on the quantum of compensation in each case and then approach J&J for claim settlement.
Rough estimates show that at a rate of Rs 1 crore per hospital bed, the investment in India alone would be around Rs 2,000 crore
Some of the popular brands that would be impacted include Phensedyl (Abbott), Tixylix (Abbott), Gluconorm PG (Lupin), Ascoril D (Glenmark), Solvin Cold (Ipca), D Cold Total (Paras Pharma).
'My wife has done everything... She has had to give up a lot,' HRD Minister Prakash Javadekar tells Sahil Makkar.
In its investor presentation, IHH said it wanted to develop Fortis into a market leader.
Experts believe the move will have little impact given limited production of generic drugs and authority of doctors in prescribing medicines.
In May, price growth for drugs was in negative territory at (-)1 per cent
Right now the challenge before the government is to double the speed of construction in order to complete the remaining 6.6 million houses before March 2019.
The number of management colleges has dropped from 3,609 in 2014-15 to 3,264 in 2017-18.
While farmers in Gujarat are rejecting the compensation package, farmers in Maharashtra say they do not wish to part with their land for a project that largely benefits Gujarat.
Their offer values Fortis at over Rs 9,000 crore, or around Rs 172 per share.
Third of faculty positions vacant. One per cent seats empty. New institutes lag in infrastructure, research.
Seven students were made international offers.
UIDAI has asked police to investigate, it was not fully convinced about nature of the incident
'Even if something appears to be wrong, we can always request the government and Parliament to make amends.'
Government gives 60 institutes freedom to fix courses, collaborate with foreign peers.
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
Vikram Kothari, managing director of Rotomac Pens, is now fighting a battle that might be difficult to win.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances